Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $477.96

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus rating of “Moderate Buy” from the twenty-eight research firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, twenty-two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $477.9604.

ALNY has been the subject of a number of analyst reports. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Royal Bank Of Canada decreased their target price on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target for the company. Finally, Chardan Capital decreased their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th.

Alnylam Pharmaceuticals Trading Up 0.0%

NASDAQ ALNY opened at $320.66 on Friday. The firm has a market cap of $42.53 billion, a PE ratio of 187.52 and a beta of 0.36. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The stock has a 50-day moving average of $352.25 and a 200-day moving average of $414.18. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s revenue was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.65) earnings per share. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease — deal includes about $10M upfront plus up to $1.13B in milestones, expanding Alnylam’s RNAi opportunity set beyond liver/rare diseases. Tenaya deal
• Positive Sentiment: Alnylam struck a multi‑year precision‑medicine agreement with Helix to accelerate target discovery and patient stratification — a collaboration that could improve R&D efficiency and help de‑risk development programs. Helix agreement
• Positive Sentiment: Coverage notes a Canada reimbursement decision for AMVUTTRA and ongoing trial progress for pipeline assets — these commercial developments improve near‑term revenue visibility for marketed RNAi drugs. AMVUTTRA reimbursement
• Neutral Sentiment: The market reaction to Tenaya’s stock after the deal (TNYA pulled back after a strong rally) shows partner‑stock volatility but does not directly change Alnylam’s deal economics. TNYA market reaction
• Neutral Sentiment: Short‑interest reports showing “0 shares” / 0.0 days to cover are likely a reporting glitch and are not a real driver of positioning today.
• Negative Sentiment: Multiple insiders, including CEO Yvonne Greenstreet and several EVPs, disclosed share sales (early March filings). Clustered insider selling can create near‑term negative sentiment and add selling pressure despite insiders still holding large stakes. CEO SEC filing InsiderTrades summary
• Negative Sentiment: Recent quarterly results (reported Feb. 12) missed EPS and revenue estimates, which keeps valuation under scrutiny and may limit upside until clearer revenue traction is sustained.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the sale, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares in the company, valued at approximately $6,989,297.80. This represents a 7.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 in the last quarter. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Groupama Asset Managment lifted its stake in Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the period. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $895,816,000. Arrowstreet Capital Limited Partnership raised its holdings in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $369,943,000. Finally, Holocene Advisors LP purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $194,616,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.